Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK

References

• Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society. International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301–315.
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Buse DC, Manack AN, et al. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86–92.
   PubMed Web of Science ®Google Scholar
• Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563–578.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Manack Adams A, Buse DC, et al. A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study and American Migraine Prevalence and Prevention (AMPP) study: demographics and headache-related disability. Headache. 2016;56(8):1280–1289.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Brin MF. Chronic migraine: An update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies. Headache. 2017;57(1):109–125.
   PubMed Web of Science ®Google Scholar
• BASH. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication-overuse headache. In: MacGregor E, Steiner T, Davies P, editors. Hull, UK: British Association for the Study of Headache; 2010.
   Google Scholar
• NICE. Clinical Knowledge Summaries: Migraine London, UK: National Institute for Health and Care Excellence; 2018 [2017 Jun 3]. Available from: https://cks.nice.org.uk/migraine
   Google Scholar
• NICE. National Instute for Health and Care Excellence Pathways: management of migraine (with or without aura) London, UK; 2017 [2017 Jun 3]. Available from: https://pathways.nice.org.uk/pathways/headaches/management-of-migraine-with-or-without-aura
   Google Scholar
• NICE [CG150]. Headaches in over 12s: diagnosis and management. London, UK: National Institute for Health and Care Excellence; 2012.
   Google Scholar
• SIGN. Pharmacological management of migraine (155): a national clinical guideline. Scottish Intercollegiate Guidelines Network; 2018 [cited 2018 July 4]. Available from: www.sign.ac.uk
   Google Scholar
• eMC. Summary of Product Characteristics - Topamax 25 mg tablets -. Surrey, UK: electronic Medicines Compendium; 2018 [cited 2018 July 4]. Available from: https://www.medicines.org.uk/emc
   Google Scholar
• eMC. Summary of Product Characteristics - Botox 200 units. Surrey, UK: electronic Medicines Compendium; 2018 [cited 2018 July 4]. Available from: https://www.medicines.org.uk/emc/
   Google Scholar
• NICE [TA260]. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. London, UK: National Institute for Health and Care Excellence; 2012.
   Google Scholar
• SMC [692/11]. 2nd Resubmission; botulinum toxin A, 50 Allergan units, 100 Allergan units, 200 Allergan units, powder for solution for injection (Botox); SMC No. (692/11). Glasgow, UK: Scottish Medicines Consortium; 2017 [cited 2018 July 4]. Available from: https://www.scottishmedicines.org.uk/
   Google Scholar
• Bendtsen L, Sacco S, Ashina M, et al. Guideline on the use of OnabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018;19(1):91.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–814.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358–1373.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–936.
   PubMed Web of Science ®Google Scholar
• Jhingran P, Osterhaus JT, Miller DW, et al. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache. 1998;38(4):295–302.
   PubMed Web of Science ®Google Scholar
• Batty AJ, Hansen RN, Bloudek LM, et al. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ. 2013;16(7):877–887.
   PubMedGoogle Scholar
• Gillard PJ, Devine B, Varon SF, et al. Mapping from disease-specific measures to health-state utility values in individuals with migraine. Value Health. 2012;15(3):485–494.
   PubMed Web of Science ®Google Scholar
• NICE [PMG9]. Guide to the methods of technology assessment. National Institute for Health and Care Excellence; 2013.
   Google Scholar
• Ahmed F, Gaul C, Garcia-Monco JC, et al. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019;20(1):26.
   PubMedGoogle Scholar
• Davies B, Gaul C, Martelletti P, et al. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. J Headache Pain. 2017;18(1):93.
   PubMedGoogle Scholar
• Frampton JE, Silberstein S. OnabotulinumtoxinA: a review in the prevention of chronic migraine. Drugs. 2018;78(5):589–600.
   PubMed Web of Science ®Google Scholar
• Ahmed F, Zafar HW, Buture A, et al. Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse. SpringerPlus. 2015;4(1):589.
   PubMedGoogle Scholar
• Dominguez C, Pozo-Rosich P, Torres-Ferrus M, et al. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. Eur J Neurol. 2018;25(2):411–416.
   PubMed Web of Science ®Google Scholar
• Khalil M, Zafar HW, Quarshie V, et al. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K. J Headache Pain. 2014;15(1):54.
   PubMedGoogle Scholar
• Negro A, Curto M, Lionetto L, et al. OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. SpringerPlus. 2015;4(1):826.
   PubMedGoogle Scholar
• Negro A, Curto M, Lionetto L, et al. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1.
   PubMed Web of Science ®Google Scholar
• Pedraza MI, de la Cruz C, Ruiz M, et al. OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. SpringerPlus. 2015;4(1):176.
   PubMedGoogle Scholar
• Alpuente A, Gallardo VJ, Torres-Ferrus M, et al. Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA. Eur J Neurol. 2019;20.
   Google Scholar
• Ahmed F, Khalil M, Tanvir T, et al. MTIS 2018 abstracts. MTIS2018-102: long term outcome for OnabotulinumtoxinA therapy in chronic migraine; a two year follow up of 508 patients from the hull migraine clinic. Cephalalgia. 2018;38(1_suppl):1–115.
   Google Scholar
• Ahmed F, Khalil M, Tanvir T, et al. MTIS 2018 abstracts. MTIS2018-103: five year outcome on 211 patients receiving OnabotulinumtoxinA for chronic migraine; data from hull migraine clinic. Cephalalgia. 2018;38(1_suppl):1–115.
   Google Scholar
• Andreou AP, Trimboli M, Al-Kaisy A, et al. Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal. Eur J Neurol. 2018;25(8):1069–1e83.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollon E, Ramon C, Larrosa D, et al. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year? Cephalalgia. 2015;35(10):864–868.
   PubMed Web of Science ®Google Scholar
• Rothrock JF, Andress-Rothrock D, Scanlon C, et al. OnabotulinumtoxinA for the treatment of chronic migraine: long-term outcome. Headache. 2011;51(Suppl 1):60.
   Google Scholar
• Office for National Statistics. National life tables: England, 1980–82 to 2014–16. Office for National Statistics; 2017 [cited 2018 July 4]. Available from: https://www.ons.gov.uk/
   Google Scholar
• NICE BNF. Botulinum toxin type A London, UK: National Institute for Health and Care Excellence; 2018 [2018 Jul 4]. Available from: https://bnf.nice.org.uk/drug/botulinum-toxin-type-a.html
   Google Scholar
• NHS. NHS reference costs 2016-2017: the main schedule London, UK: National Health Service; 2017 [2018 Jul 4]. Available from: https://improvement.nhs.uk/resources/reference-costs/
   Google Scholar
• Curtis L, Burns A. Unit costs of health and social care 2017 University of Kent, Canterbury: Personal Social Services Research Unit; 2017 [cited 2018 July 4]. Available from: https://doi.org/10.22024/UniKent/01.02/65559
   Google Scholar
• NHS. Prescription cost analysis - England 2017: National Health Service; 2017. [2018 Jul 4]. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/prescription-cost-analysis-england-2017
   Google Scholar
• Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology. 2011;77(15):1465–1472.
   PubMed Web of Science ®Google Scholar
• Torres-Ferrus M, Quintana M, Fernandez-Morales J, et al. When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia. 2017;37(2):104–113.
   PubMed Web of Science ®Google Scholar